STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRDN
  4. [Form 4] Viridian Therapeutics, Inc.\DE Insider Trading Activity

VRDN insider filing: Fairmount now owns 3,914,458 shares

Filing Impact
(Very High)
Filing Sentiment
(Very Positive)
Form Type
4

Rhea-AI Filing Summary

Viridian Therapeutics (VRDN) reported an insider purchase on a Form 4. On 10/23/2025, Fairmount Healthcare Fund II LP acquired 454,545 shares of common stock at $22 per share (transaction code P). Following the trade, the fund beneficially owned 3,914,458 shares, held indirectly.

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the securities held by Fairmount Healthcare Fund II LP, and they disclaim beneficial ownership except to the extent of their pecuniary interest. The reporting persons are indicated as a Director and 10% Owner, and the form was filed by more than one reporting person.

Positive

  • None.

Negative

  • None.
Insider Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Fairmount Healthcare Fund II L.P.
Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner
Bought 454,545 shs ($10.00M)
Type Security Shares Price Value
Purchase Common Stock 454,545 $22.00 $10.00M
Holdings After Transaction: Common Stock — 3,914,458 shares (Indirect, Fairmount Healthcare Fund II LP)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did VRDN insiders report on Form 4?
Fairmount Healthcare Fund II LP acquired 454,545 shares of common stock at $22 on 10/23/2025.

How many VRDN shares were beneficially owned after the transaction?
Following the reported transaction, the fund beneficially owned 3,914,458 shares, held indirectly.

What is the relationship of the reporting persons to VRDN?
They are indicated as a Director and 10% Owner.

Who has voting and investment power over the acquired VRDN shares?
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over the fund’s holdings.

Was the ownership reported as direct or indirect?
The ownership was reported as indirect through Fairmount Healthcare Fund II LP.

What was the transaction code used in the filing?
The filing lists transaction code P, indicating an open-market or private purchase of non-derivative securities.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC
(Last) (First) (Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/23/2025 P 454,545 A $22 3,914,458 I Fairmount Healthcare Fund II LP(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Fairmount Funds Management LLC
(Last) (First) (Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Fairmount Healthcare Fund II GP LLC
(Last) (First) (Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Fairmount Healthcare Fund II L.P.
(Last) (First) (Middle)
200 BARR HARBOR DRIVE
SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Remarks:
The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.
/s/ Peter Harwin, Managing Member of Fairmount Funds Management LLC 10/27/2025
/s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II GP LLC 10/27/2025
/s/ Peter Harwin, Managing Member of Fairmount Healthcare Fund II L.P 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR